Tiapamil (INN; also known as dimeditiapramine) is a calcium antagonist or calcium channel blocker.[1][2] It is an experimental drug that has never been marketed.[3]
Tiapamil has been described as an antianginal agent. It exhibits properties of anti-arrhythmic medications. These are medications that are used to treat unusually fast or irregular heartbeats. Examples of arrhytmthic conditions include atrial fibrillation, atrial flutter, and super-ventricular tachycardia.[4] Upon research, the drug shows promising effects on treatment of these condition. Research seeks to create a treatment with tiapamil in order to mitigate the side effects of the more commonly prescribed calcium antagonist and anti-hypertensive verapamil. The two drugs have similar properties; however, tiapamil appears to treat arrhythmic conditions without many of the hypotensive, negative inotropic, and negative chronotropic side effects. Tiapamil is a calcium channel blocker that acts on the slow calcium channels. It can treat ventricular arrhythmias to a higher degree than traditional calcium antagonists.[medical citation needed]
^Cocco G, Chu D, Strozzi C (April 1979). "Dimeditiapramine (Ro 11-1781), a new calcium antagonist, in the management of supraventricular tachyarrhythmias in patients with acute myocardial infarction". Clinical Cardiology. 2 (2): 131–134. doi:10.1002/clc.4960020208. PMID262567. S2CID38589956.